In 2024, 11 partners exercised commercial options including BMS, NextPoint, Regeneron, REGiMMUNE, SixPeaks Bio, Santa Ana Bio, Triveni Bio, and Werewolf, among others. Antibody Discovery: Adimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback